Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Impact of insurance on survival in patients < 65 with head & neck cancer treated with radiotherapy.

  • Authors : Sittig MP; Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.; Luu M

Subjects: Head and Neck Neoplasms/Head and Neck Neoplasms/Head and Neck Neoplasms/*economics ; Insurance, Health/Insurance, Health/Insurance, Health/*statistics & numerical data ; Squamous Cell Carcinoma of Head and Neck/Squamous Cell Carcinoma of Head and Neck/Squamous Cell Carcinoma of Head and Neck/*economics

  • Source: Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery [Clin Otolaryngol] 2020 Jan; Vol. 45 (1),Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 101247023 Publication Model: Print-Electronic Cited Medium:

Record details

×
Academic Journal

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment.

  • Authors : Lele SJ; Department of Otolaryngology and Head Neck Surgery, Louisiana State University of Health Sciences, Shreveport, Louisiana, USA.; Adilbay D

Subjects: Neoplasm Recurrence, Local*/Neoplasm Recurrence, Local*/Neoplasm Recurrence, Local*/diagnostic imaging ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/genetics ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/diagnostic imaging

  • Source: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head Publisher: Wiley Country of Publication: England NLM ID: 8508176 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6817

Record details

×
Academic Journal

Radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma: biological angle.

  • Authors : Li CX; Department of Oral and Maxillofacial Oncology & Surgery, School / Hospital of Stomatology, The First Affiliated Hospital of Xinjiang Medical University, No. 137 Liyushan South Road, Urumqi, 830054, China. .; Stomatological Research Institute of Xinjiang Uygur Autonomous Region, Urumqi, 830054, China. .

Subjects: Radiation Tolerance* ; Head and Neck Neoplasms*/Head and Neck Neoplasms*/Head and Neck Neoplasms*/radiotherapy ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/radiotherapy

  • Source: Oral and maxillofacial surgery [Oral Maxillofac Surg] 2024 Jun; Vol. 28 (2), pp. 547-555. Date of Electronic Publication: 2023 Nov 08.Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101319632 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer.

  • Authors : Willemsen ACH; Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, the Netherlands; GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, the Netherlands

Subjects: Clinical Decision Rules*; Enteral Nutrition/Enteral Nutrition/Enteral Nutrition/*standards ; Gastrostomy/Gastrostomy/Gastrostomy/*standards

  • Source: Clinical nutrition (Edinburgh, Scotland) [Clin Nutr] 2022 Jan; Vol. 41 (1), pp. 177-185. Date of Electronic Publication: 2021 Nov 24.Publisher: Elsevier Country of Publication: England NLM ID: 8309603 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1983

Record details

×
Academic Journal

Prognostic Significance of SASP-Related Gene Signature of Radiation Therapy in Head and Neck Squamous Cell Carcinoma.

  • Authors : Lee MK; Department of Biomedical Science and Technology, Graduate School, Kyung Hee University, Seoul, Republic of Korea.; Woo SR

Subjects: Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/genetics ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/radiotherapy ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/mortality

  • Source: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Sep 04; Vol. 23 (9), pp. 1348-1359.Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model:

Record details

×
Academic Journal

Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell Carcinoma.

  • Authors : Forster M; UCL Cancer Institute/University College London Hospitals NHS Foundation, London, United Kingdom.; Brana I

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/adverse effects ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model:

Record details

×
Academic Journal

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

  • Authors : Hagiwara K; Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan.; Matsuki T

Subjects: Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/drug therapy ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/blood

  • Source: Anticancer research [Anticancer Res] 2024 Sep; Vol. 44 (9), pp. 4057-4072.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma.

  • Authors : Matsumura S; Department of Head and Neck Surgery, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.; Kaira K

Subjects: Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/immunology ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/therapy ; Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/Squamous Cell Carcinoma of Head and Neck*/pathology

  • Source: Anticancer research [Anticancer Res] 2024 Sep; Vol. 44 (9), pp. 4049-4056.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model: Print Cited Medium: Internet

Record details

×
Academic Journal

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.

  • Authors : Dzienis M; Cancer Department, Gold Coast University Hospital, Southport, QLD, Australia.; Cundom J

Subjects: Carboplatin*/Carboplatin*/Carboplatin*/administration & dosage ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/administration & dosage ; Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/Antibodies, Monoclonal, Humanized*/therapeutic use

  • Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 01; Vol. 42 (25), pp. 2989-2999. Date of Electronic Publication: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium:

Record details

×
  • 1-10 of  2,199 results for ""HEAD & neck cancer""